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Abstract
Nicotine exerts its oncogenic effects through the binding to nicotinic acetylcholine receptors (nAChRs) and the activation of
downstream pathways that block apoptosis and promote neo-angiogenesis. The nAChRs of the a7 subtype are present on a
wide variety of cancer cells and their inhibition by cobra venom neurotoxins has been proposed in several articles and
reviews as a potential innovative lung cancer therapy. However, since part of the published results was recently retracted,
we believe that the antitumoral activity of cobra venom neurotoxins needs to be independently re-evaluated. We
determined the activity of a-neurotoxins from Naja atra (short-chain neurotoxin, a-cobrotoxin) and Naja kaouthia (long-
chain neurotoxin, a-cobratoxin) in vitro by cytotoxicity measurements in 5 lung cancer cell lines, by colony formation assay
with a7nAChRs expressing and non-expressing cell lines and in vivo by assessing tumor growth in an orthotopic Non-Obese
Diabetic/Severe Combined Immunodeficient (NOD/SCID) mouse model system utilizing different treatment schedules and
dosages. No statistically significant reduction in tumor growth was observed in the treatment arms in comparison to the
control for both toxins. Paradoxically a-cobrotoxin from Naja atra showed the tendency to enhance tumor growth
although, even in this case, the statistical significance was not reached. In conclusion our results show that, in contrast with
other reports, the nAChR inhibitors a-cobratoxin from N. kaouthia and a-cobrotoxin from N. atra neither suppressed tumor
growth nor prolonged the survival of the treated animals.
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Introduction
The experimental evidences suggesting that stimulatory or
inhibitory neurotransmission is involved in cancer development,
progression and in the response to therapy have steadily accu-
mulated [1]. Indeed, tobacco components regulate cellular
functions related to cell transformation and are involved with
smoking addiction and lung cancer predisposition and develop-
ment by directly interacting with neuronal and non-neuronal
nicotinic acetylcholine receptors (nAChRs) [2,3,4,5,6,7,8,9,10,11].
Nicotine itself has limited lung cancer initiating capabilities but
can sustain tumor growth and promote metastatic spread through
its antiapoptotic and neoangiogenic properties [2,7,12].
The expression of nAChRs in non-neural cells of the lung, and
particularly in the airway epithelium, reflects the multiple essential
functions exerted by the cholinergic system in normal lung
development and function [13,14]. In this respect, it has been
proposed that the role of nAChRs in lung cancer might be similar
to that of estrogen receptors in breast cancer since in both cases
the inappropriate stimulation of the receptors contributes to
cancer development [15]. In view of the high level of expression of
certain subtypes of nAChRs in lung cancer cells compared to the
surrounding unaffected tissue [16,17] and of supporting experi-
mental evidences [18,19,20,21], it was hypothesized that antag-
onists of nAChRs, and in particular cobra a-neurotoxins, could be
exploited as potential therapeutic agents [22,23,24]. However, the
limited knowledge of the functionality and of the long-term effects
of the stimulation of these receptors in cancer cells [2,25,26] and,
most importantly, the recent retraction of a report supporting the
antitumoral effects of cobra a-neurotoxins in vitro and in vivo [27]
renders questionable the targeting of nAChRs with these toxins for
lung cancer treatment.
Cobra venom is constituted by many polypeptides with multiple
toxic activities. Among these, the three-fingered toxins (TFTs) are
the main components and are represented by a-neurotoxins and
cytotoxins. The a-neurotoxins bind to nAChR with different
specificity and affinity: short-chain toxins (60–62 amino acid
residues, 4 disulfide bridges) block muscle-type nAChRs whereas
long-chain toxins (66–75 amino acid residues, 5 disulfide bonds,
the fifth bond being present in the central polypeptide loop) in
addition to muscle-type nAChRs block also the neuronal receptors
[28,29]. As an example of short-chain toxins, a-neurotoxin called
a-cobr*o*toxin from Naja atra cobra venom can be mentioned.
The principal a-neurotoxin from Naja kaouthia cobra venom called
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20695a-cobr*a*toxin is an example of long-chain toxins. The short-
chain toxins are structurally related to the cytotoxins that non-
selectively kill the cells [30].
While reviewing the literature on the anti-tumor effects of
a-cobratoxin [18,19,20,21,22,27] we realized that the various
reports presented major differences on the dosage of the toxin
utilized for the in vivo experiments, on the number of injected cells
and on mice survival. Also the presence of the a7 nAChR on the
cell line utilized for the in vivo studies was uncertain since
conflicting results are present in the literature [22,31]. Further-
more, since part of the data were retracted with no specific
motivation [27], we felt necessary to re-evaluate the anti-cancer
properties of cobra neurotoxins in vitro and in vivo in a clinically
relevant animal model of lung cancer [18] to clarify if these toxins
could be considered the prototype of a novel class of natural
products with antitumor properties as proposed [15,22,24].
Results and Discussion
Expression of a7 nAChR in A549 and A549-luc cells
The interaction between a-cobratoxin and the a7 nicotinic
receptor [32] was one of the experimental evidences behind the
rationale of utilizing cobra venom toxins as anticancer agents [22].
Although this receptor is expressed on a wide spectrum of tissues
and cell lines, a recent survey of the literature [22,31] reported
conflicting data on the expression of this receptor in A549, the cell
line utilized for the in vivo and most of the in vitro anticancer assays
on a-cobratoxin. Therefore, as an initial step to verify the activity
of a-cobratoxin in NSCLC, we performed a semiquantitative RT-
PCR and qPCR survey to demonstrate the expression of a7
nAChR in 5 lung cancer cell lines. Three of the cell lines utilized in
the present study (A549, H1650 and SK-MES 1) were the same of
the original set of experiments [18,19,20,27]. As shown in Figure 1,
Panel A, the a7 nicotinic receptor was readily detectable in A549,
H1650 and SK-MES 1 but not in H1975 and CALU 1. The
qPCR analysis confirmed the presence of different amount of the
a7 nAChR mRNA in A549, H1650 and SK-MES 1 (Figure 1,
Panel B). In agreement with the RT-PCR results, in H1975 and
CALU 1 the a7 nAChR transcript, using the same amount of
cDNA used for all the cell lines, appeared after cycle 40, a result
that could be attributed either to an extremely low level of
expression or to background noise
The expression of a7 nAChR at the protein level was confirmed
by western blot analysis in A549 and A549-luc cells (Figure 1,
Panel C).
It has been reported that stimulation of a7 nAChR in human
lung cancer cells results in the up regulation of this receptor [33].
We have tested the influence of the a-neurotoxins from N. atra and
N.kaouthia on the level of a7 nAChR focusing on A549 and A549-
luc.
The qPCR analysis showed that the treatment with either
a-cobrotoxin or a-cobratoxin at the concentration of 0.003 mM,
the reported IC50 for a-cobratoxin in A549 [20], together with
concentrations three times lower (0.001 mM) and three times
higher (0.009 mM), did not substantially change the level of
expression of the receptor in these cell lines (less than two-fold
change, Figure S1).
In vitro effects of short- and long-chain a-neurotoxins on
NSCLC cell lines
Early in vitro experiments suggested that the effect of
a-cobratoxin is dose dependent and that the high selectivity and
specificity of this molecule depends from the density of a7 nAChR
[20,21]. In this respect non-tumoral pulmonary cells as well as
other primary unaffected cells expressing low levels of a7 receptors
were remarkably resistant to a-cobratoxin treatment [20].
To evaluate the cytotoxic activity of a-cobratoxin, that
efficiently binds to the a7 nAChR (see Materials and Methods)
and the specificity and selectivity of its action, we performed MTT
assays with the short- and long-chain a-neurotoxins on presum-
ably sensitive a7 nAChR-positive and presumably resistant a7
nAChR–negative cell lines. Dose-response curves were drawn to
assess the drug concentration reducing survival. The initial
cytotoxicity experiments were carried out utilizing toxins concen-
trations that in other publications were reported to be effective in
a7 nAChR-positive NSCLC cell lines but not toxic in normal cells
(IC50: 0.003 mM for A549, 0.04 mM for SK-MES 1 and 1 mM for
H1650) [18,20,21,22]. However, at these concentrations we could
not detect appreciable cytotoxic activity and the IC50 could not be
reached with any of the two toxins (data not shown).
At higher concentrations (up to 30 mM) the a-cobrotoxin
showed a limited non dose-dependent toxicity that remained
essentially constant in a wide range of concentrations in all 5 cell
lines (Figure 2, Panel A).
At high concentrations the a-cobratoxin showed a clear dose-
dependent toxicity (Figure 2, Panel B). However the IC50
concentration observed in our study for A549 and SK-MES 1 was
2466 and 105 fold higher than that reported in an earlier publication
[20]. The difference was much lower for H1650 (2.9 fold) a result
compatible with the utilization of a different toxin preparation.
The limited toxic effect of the short chain a-cobrotoxin could be
explained by its inability to bind to the a7 receptor. Surprisingly
however, the a-cobratoxin was effective also on a7 nAChR-
negative cells suggesting that the toxic activity is not mediated by
the binding of the toxin to the a7 receptor.
To confirm and extend this observation we have conducted
a colony formation assay with the a7 nAChR+A549 and with
the a7 nAChR2NCI-H1975 cell lines . Since the IC50 was
not reached with a-cobrotoxin, we utilized the two highest
concentrations tested by MTT (15 and 30 mM). For a-cobratoxin
we utilized the concentrations corresponding to the IC50 for A549
and NCI-H1975 (7. 5 and 3 mM, respectively) and concentrations
corresponding to half and twice the IC50. As shown in Figure 3,
the clonogenic activity of the two cell lines was not affected by the
treatment and by the presence of the a7 nACh receptor.
The activation of the apoptotic cascade was considered the key
effect of the binding of the a-cobratoxin to the a7 nAChR
[18,20,21,22]. In view of the major differences between our results
and those previously published regarding the dosage at which the
IC50 could be obtained and the absence of selective action of a-
cobratoxin on a7 nAChR-positive cells, we tried to understand if
activation of apoptosis indeed occurs upon treatment with a-
cobratoxin by Annexin V-PI flow cytometry staining. It was
reported that the maximum induction of apoptosis in A549 cells
could be obtained by treatment with 1 mM toxin for 24 hours [18].
We have repeated the same experiment utilizing the same
methodology but with toxin concentrations (1, 10 and 50 mM) that
induced growth inibition ranging from 5 to 87% in MTT assays.
As shown in Figure 4, even at the highest concentration very few
cells (1–3%) presented evidences of apoptosis with necrotic cells
being prevalent.
Overall theseresults suggest that the celldeathobserved invitrois
likelythe result ofnecrosisratherthantheactivationoftheapoptotic
pathway following the specific binding of a-cobratoxin to its ligand.
In vivo toxicity of a-neurotoxins
The acute toxicity of increasing doses of toxins after i.v.
administration (as in M&M) was assessed in CD1 mice on the
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within 15 minutes after injection and were mostly characterized
by general discomfort and respiratory distress that restored to the
normal conditions within 60–180 minutes. Based on the number
of dead CD1 mice, following administration of either a-
cobrotoxin or a-cobratoxin and over an observation period of
14 days, the LD values were determined and the MTD identified
as 0.1 mg/kg for a-cobrotoxin and 0.2 mg/kg for a-cobratoxin
as shown in Table 1.
Importantly, the LD50 for a-cobrotoxin determined in our
study (0.128 mg/kg) was in very good agreement with literature
data (0.1 mg/kg: http://www.uniprot.org/uniprot/P60770). The
observed LD50 for a-cobratoxin was 0.35 mg/kg, a value in the
same order of magnitude of the literature data (0.1 mg/kg; http://
www.uniprot.org/uniprot/P01391).
The reports on the in vivo toxicity of a-cobratoxin are confusing
and in the recent literature we have observed that the LD50
concentration reported in three different publications from the same
Figure 2. Cytotoxicity assay. The NSCLC cell lines A549, NCI-H1975, H1650, CALU 1 and SK-MES 1 were incubated for 72 hours with a-cobrotoxin
(0.6–30 mM), upper panel, or a-cobratoxin (0.75–50 mM), lower panel, and the toxicity was measured with the colorimetric MTT test. The IC50 was
reached only with a-cobratoxin.
doi:10.1371/journal.pone.0020695.g002
Figure 1. Presence of the a7-nACh receptor on NSCLC cell lines. A) Semiquantitative Alpha7 RT-PCR analysis on Human NSCLC
adenocarcinoma e squamous cell carcinoma cell lines. GAPDH expression was utilized as internal control for mRNA integrity and cDNA quantification.
NCI-H1975 and Calu1 are negative. C: No template control. B) qPCR alpha 7 expression in the same cell lines. On y-axis natural logaritm (ln) of fold
change. NCI-H1650 was used as calibrator, GAPDH as reference gene. One ugr of Total RNA was retrotrascibed and the same amount of cDNA per
sample (2 ul) was used (Ct GAPDH comprised between 15.65 and 17.65). NCI-H1975 and Calu1 resulted negative or with extremely low expression
due to Ct.40. C) Western blot analysis for alpha 7. PC12 was loaded as positive control. Actin expression was utilized as internal control.
doi:10.1371/journal.pone.0020695.g001
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The results obtained in the present study are essentially in agreement
with those of two of the previous reports [18,21] and, importantly,
demonstrate the biological activity in vivo of our toxin preparations.
Half of the MTD for each toxin (0.05 and 0.1 mg/kg,
respectively) were then used in one of the two treatment
protocols designed to assess the antitumor activity in vivo of
these toxins.
Figure 3. Clonality assay. The cell lines A549 (a7 AChR +) and NCI-H1975 (a7 AChR -) were plated in 35 mm Petri dishes or in 24 wells plates at
densities of 150 (A549) and 300 (NCI-H1975) cells/dish and exposed to either long-chain a-neurotoxin from Naja Kaouthia, at concentrations of
15 mM, 7.5 mM, 3.8 mM (A549) and 6 mM, 3 mM, 1.5 mM (NCI-H1975), or short-chain from Naja Atra, at concentrations of 30 mM and 15 mM (both cell
lines). Treated cells were then incubated for 7–10 days, until visible colonies formed.
doi:10.1371/journal.pone.0020695.g003
Figure 4. Evaluation of the Apoptosis elicited by a-cobratoxin in A549 cells. Cells were incubated for 24 hours with 1, 10 and 50 mM a-
cobratoxin and apoptosis was evaluated by Annexin V-PI staining and FACS separation. Apoptosis in untreated cells was 0.63% and in treated cells
was in the range 0.98–2.32%.
doi:10.1371/journal.pone.0020695.g004
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To assess the antitumor activity of both toxins, NOD/SCID mice
were orthotopically transplanted with 0.5610
6 human A549-luc
cells/in a volume of 10 ml PBS into the right lung. As surrogate
marker of tumor growth we measured the light emission of the
luciferase-tagged A549 cells; this system enabled us to longitudi-
nally follow each animal and to monitor the effect of the
treatment.
Following the assessment of tumor implants, by IVIS detection,
the mice were randomly assigned to one of the study groups and
treatment started 7 days after orthotopic transplantation according
to the two different protocols outlined in Figure 5.
Protocol 1: 8 animals were assigned to receive i.v. 0.12 mg/kg of
toxin (1/1000 of the LD10 indicated in [20]), three times a week
for three weeks according to a previously reported schedule [20]
and 8 animals received vehicle alone.
Protocol 2: 8 animals were treated i.v. once a week for three
weeks with of 0.05 mg/kg of a-cobrotoxin or 0.1 mg/kg of a-
cobratoxin (corresponding to half-MTD). For a-cobratoxin the
half-MTD corresponds to 12.8 mM, a concentration that in vitro
should kill between 50 and 63% of the A549 cells. Eight control
animals received vehicle alone.
In another publication [18] where the time-schedule of protocol
1 was utilized, the reported a-cobratoxin dosage was 0.12 mg/kg.
On the basis of our in vivo toxicity determination we considered
this dosage too high to be administered for three consecutive days
to mice with compromised respiratory function.
After an initial assessment of tumor growth at day 7, the
antitumoral activity induced by toxins was evaluated in treated
and untreated mice, at days 14, 21 and 28 post-administration in
both protocols. We have observed that at the initial stages of
growth, the bioluminiscence of the animals closely represented the
extent of tumor growth. Conversely, at later stages, tumor necrosis
and reduced perfusion, likely diminished the light emission in mice
even when the tumor had completely invaded the thoracic cavity
and, in most cases, had extended outside the thorax.
The pre-treatment IVIS evaluation of the 56 mice included in
the study at day 7 showed successful tumor growth in all animals
in spite of a 300-fold individual variability (average photon
emission: 5.5610
7/mouse, range 6.68610
522.06610
8). There-
fore, for data analysis, we considered the fold-change of emission
between treated and non-treated animals at each treatment time
point (14, 21 and 28 days) rather than the absolute photon
emission values [18].
In Figure 6, we report the raw IVIS determination in each mice
treated with a-cobrotoxin according to schedule 1 and in the
corresponding control group. As shown, this treatment does not
seem to have an appreciable effect on tumor growth in this animal
model system. The only apparent striking difference was the
number of dead animals at the end of the observational period (4
in the control group and 2 in the treatment group). However, it
must be noticed that at this time all animals had to be sacrificed for
ethical reasons and that autopsy revealed that the tumor had
extended outside the thoracic cavity in all treated and untreated
mice. As shown in Figure 7 also at the higher dosages utilized in
the schedule 2 treatment plan, the effect of a-cobrotoxin as
antitumor agent was negligible, if any. As for the schedule 1
treatment plan, also these animals were sacrificed at day 28
because of tumor growth-related symptoms. Indeed, at autopsy all
animals presented a completely invaded thoracic cavity with
tumors extending outside the chest irrespective of treatment
scheme.
In Figure 8 is reported the averaged fold-change of emission in
the treatment and control arms for schedule 1 (Panel A) and
schedule 2 (Panel B). Although the difference, evaluated by the
Table 1. In vivo toxicity of a-cobrotoxin and a-cobratoxin.
CbTx (mg/kg) i.v. Dead/Overall LD Dead/Overall LD
a-cobrotoxin a-cobratoxin
5 1/1 100
1 1/1 100
0.5 1/1 100 3/3 100
0.4 2/3 60
0.35 2/4 50
0.30 1/3 30
0.25 2/2 100
0.20 4/4 100 0/2 MTD
0.16 4/4 100
0.135 4/5 80
0.130 3/4 75
0.128 2/4 50
0.125 1/6 16 0/2 -
0.100 0/2 MTD 0/2 -
doi:10.1371/journal.pone.0020695.t001
Figure 5. Treatment schedules for in vivo studies. Mice were injected with 0.5610
6 human A549-luc cells. At day 7, after the IVIS determination,
the animals were randomized and subjected to treatment. For schedule 1 the mice were treated with 1/1000 of the LD10 as indicated in [20] three
times/week for three weeks. For schedule 2 the mice were treated once a week with a dosage corresponding to K MTD (determined in the present
study).
doi:10.1371/journal.pone.0020695.g005
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animals.
doi:10.1371/journal.pone.0020695.g006
Figure 7. Raw IVIS determination of tumor growth in mice treated with a-cobrotoxin according to schedule 2. X denotes the dead
animals.
doi:10.1371/journal.pone.0020695.g007
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for schedule 1, day 14, p=0.04), we observed a striking higher
emission in the toxin treatment group with respect to the control
arm. This effect was dramatically evident in the schedule 2 at day
28, although, the difference in the photon emission did not reach
statistical significance, likely because of the limited number of
animals,
The same treatment schedules were also utilized with the a-
cobratoxin. The results of this set of experiments showed that this
toxin lacks evident antitumoral activity as well. In Figure 9, we
report the raw IVIS determination for each mice treated with a-
cobratoxin according to schedules 1 and 2 while in Figure 8, Panel
C, we show the average fold-change of emission in the control and
treated mice. As can be seen, the treatment does not appreciably
influence tumor growth as photon emission in treated mice was
comparable to that of the controls at each time-point. The number
of animals that had to be sacrificed for humanitarian reasons
before the end of the observational period was higher in control as
compared to treated mice. However, it must be pointed out that
also in this case all animals, at day 28, presented massive tumor
growth that extended outside the thoracic cavity irrespectively of
the treatment plan.
The in vivo experiments were conducted only with the A549-luc
cell line since the utilization of non-luc tagged cells would have
required a large number of mice to assess the antitumor activity of
the toxins. In view of the results obtained in vitro on 5 cell lines and
in vivo with A549-luc we considered unethical to precede with
additional animal studies
The molecular basis of lung cancer have been extensively
studied and the interaction between nicotine and nAChRs has
been recognized as one of the key events leading to the
development of this tumor [2,4,5,6,7,8,9,10,11,16,26]. It is thus
not surprising that nAChRs were considered as good candidate
targets for innovative ‘‘biologic’’ therapies [15,22,23,24]. In this
respect, the existence of potent toxins inhibiting nACh receptors
might open the possibility of adapting the Paul Ehrlich’s ‘‘magic
bullet’’ concept to lung cancer therapy [34].
The cobra snake venom is a source of different toxins possessing
cytolytic and nAChR inhibiting activities [32,35]. Because of this
latter activity, the a-cobratoxin from N. kaouthia has been proposed
as an innovative natural therapeutic agent for lung cancer
[18,19,20,22,24] capable of dramatically inhibit lung tumor cells
growth and to significantly improve the survival of lung tumor-
bearing mice. We have re-evaluated the antitumoral activities of
two different cobra neurotoxins in vitro and in vivo utilizing two
schedules of administration and the same experimental conditions
of previous reports. The results of our experiments clearly show
that these two biologically active toxins have essentially no effects
on tumor cell growth in in vitro assays at the concentration reported
in other publications. A significant tumor cell growth inhibition
was obtained at a-cobratoxin concentration too high to be utilized
in vivo. Importantly a-neurotoxins, at concentrations usable in vivo,
did not inhibit tumor growth nor were capable of significantly
prolonging the survival in mice bearing an orthotopically-grafted
NSCLC. Indeed, the in vivo experiments had to be interrupted at
day 28, or earlier, in treated and untreated experimental animals
for ethical reasons since in all cases the grafted tumor had
extended outside the thorax. These results are in striking contrast
with those of other studies that reported an increased lifespan of
93% in a-cobratoxin treated versus untreated mice [20] and
suggest that cobra a-neurotoxins have no potential therapeutic
effect in lung cancer.
It remains to be explained why in one published report from the
same group all animals had to be killed for humanitarian reasons
at day 29 [18] while in another study the animals, similarly
treated, could be followed up to day 170 [20], (reviewed in [22]).
Surprisingly we have observed that the in vivo tumor growth in
the mice treated with a-cobrotoxin was higher than that of the
control groups. This unexpected finding might suggest that
although this toxin does not bind to the a7 receptor, the reported
predominant subtype present on A549 cells, it might activate the
nicotine-dependent tumorigenic pathway through its binding to
different nAChR (most probably to muscle-type receptor). Thus,
this toxin may be an excellent tool for finely dissecting the
biological pathways where the nAChRs are involved.
Materials and Methods
Ethics statement
All the details about: permissions, regulations and animal
welfare are reported in the ‘‘Animals’’ sub-section of this Methods
section.
Tumour cell lines and a-neurotoxin preparations
The rat pheochromocytoma cell line PC12, utilized as positive
control for a7 nAChR expression, the human NSCLC adenocar-
cinoma cell lines H1650 and H1975 were obtained from the
ATCC; the NSCLC adenocarcinoma A549 and the squamous
carcinoma cell lines SK-MES 1 and CALU 1, were obtained from
our Institutional Cell Repository (ICLC, www.iclc.it). The cell line
A549-luc, modified to stably express luciferase, and utilized for in
vivo studies was kindly provided by Dr. J.W. Shay (H. Simmons
Comprehensive Cancer Center, University of Texas, Dallas). The
A549, A549-luc, SK-MES 1 and H1650 utilized in the present
study had the same origin of those utilized in other published
works [18,19,20,27]. Cells were grown in RPMI 1640 with 10%
bovine serum. (Invitrogen, San Giuliano Milanese, Italy).
The short-chain a-cobrotoxin from N. atra (MW 6949 kDa) was
obtained from Sigma (Milano, Italy). The LD50 in mice of the
batch utilized in this work, determined by the Company, was
0.09 mg/kg.
The long-chain a-cobratoxin (MW 7821 kDa) was purified
from N. kaouthia venom as described [36]. The procedure involves:
gel-filtration, high performance ion-exchange and reversed-phase
chromatography and is utilized to produce large quantities of the
toxin for receptor studies [37]. The a-cobratoxin prepared by this
method is fully active and inhibited acetylcholine-induced currents
in Xenopus oocytes expressing human a7 nicotinic acetylcholine
receptor with IC50 of 4.1 nM [38]. The biologic activity of the
batch of toxin utilized in this study was tested for ability to inhibit
radioactive a-bungarotoxin binding to human a7 nicotinic
acetylcholine receptor heterologously expressed in GH4C1 cells.
At 20 nM a-cobratoxin inhibited a-bungarotoxin binding by more
than 50%.
The lyophilized toxins were dissolved at the stock concen-
tration of 10
23 M in Phosphate-Buffered Saline (PBS) and kept
at 220uC.
Western blot analysis
Cell suspensions were obtained after trypsinization of A549 or
A549-luc and PC12 cultures (used as positive control). Cells were
dissolved in lysis buffer and processed as previously described [39].
The protein concentration of cell lysates was determined by the
Bio-Rad Protein Assay (Bio-Rad Laboratories, Segrate, Italy)
according to the manufacturer’s instructions.
Fifty mg of total proteins were separated on NuPAGE 4–12%
bis-Tris gel (Invitrogen, San Giuliano Milanese, Italy) and then
Lack of Antitumor Activity of Cobra a-Neurotoxins
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TM Gel
Tranfer Stacks (Invitrogen).
Blots were probed with the anti a7 AChR polyclonal antibody
(Santa Cruz, Heidelberg, Germany) and subsequently with anti-
ßActin monoclonal antibody (Sigma, Milano, Italy) to ascertain
that an equal amount of protein was loaded in each lane.
Immunodetection was performed using the enhanced chemilu-
minescence (ECL) kit (GE Healthcare, Milano, Italy) following the
supplier’s recommended procedures.
RT and qPCR analysis
Total RNA from A549-luc (untreated and treated with 1, 3
and 9 nM of a-cobratoxin or a-cobrotoxin for 72 h), A549
(untreated and treated with 1, 3 and 9 nM of a-cobratoxin),
H1650, H1975 , SK-MES 1, CALU 1 and PC12 cell lines was
isolated using the RNAeasy Mini Kit (Qiagen) following the
manufacturer instructions. RNA was treated with RNAse-free
DNAse during on-column purification. RNA integrity was
assessed by gel electrophoresis: ratio of 28S to 18S was
approximately 2:1. RNA was quantified by spectrophotometry.
The ratio of the readings at 260 nm and 280 nm was comprised
between 1.9 and 2.1.
One mg of total RNA was used to prepare cDNA with the
SuperScript
TM II RNase H- Reverse Trascriptase (Invitrogen)
according to the manufacturer instructions.
To determine the presence of a7 nAChR on cell lines,
cDNA were used in a semiquantitative reaction as elsewhere
described [40,41,42].
PCR conditions were: 95uC for 10 min, 45 cycles 95uC for
15 sec, 55uC for 15 sec and 72uC for 30 sec).
qPCR reactions were performed using Maxima Sybr Green
qPCR Master Mix (Fermentas GMBH, St. Leon-Rot , Germany),
0.3 mM of each primer and nuclease-free water in a total volume
of 25 ml. Relative expression was calculated using as calibrator
A549-luc with ß2 Microglobulin as the reference gene. The
reactions were performed using the Mastercycler ep RealPlex
instrument and its analytical software (Eppendorf, Milano, Italy).
PCR conditions were: 95uC for 10 min, followed by 45 cycles as
follow: 95uC for 15 sec, 50uC for 30 sec and 72uC for 30 sec.
Specificity of the reaction was controlled by melting curve analysis
ramping from 60uCt o9 5 uC in 20 minutes.
Two independent quantitative PCR reactions were performed
for each sample.
The sequences of the primers for RT and qPCR were: forward
59-GCCAATGACTCGCAACCACTC-3; reverse 59-CCAGCG-
TACATCGATGTAGCA-39. These primers encompass bases
236–571 of the human a7 nAChR, Genbank accession number
X70297 [33]. . The same primers are used also on PC12 positive
control cell lines: human and rat target sequences have 84%
overall homology and complete identity in the crucial 39-terminal
sequence.
Cytotoxicity, colony formation assay and apoptosis
detection in vitro
The colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) test was used to determine the sensitivity
Figure 8. Fold-Change of bioluminescence emission in tumor-bearing mice. Panel A: mice treated with a-cobrotoxin according to schedule
1. Panel B: mice treated with a-cobrotoxin according to schedule 2. Panel C: mice treated with a-cobratoxin according to schedules 1 and 2.
doi:10.1371/journal.pone.0020695.g008
Figure 9. Raw IVIS determination of tumor growth in mice treated with a-cobratoxin according to schedules 1 and 2. X denotes the
dead animals.
doi:10.1371/journal.pone.0020695.g009
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3 cells) H1650, H1975 , and
CALU 1 (3610
3 cells) cell lines towards increasing concentrations
of toxins (from 0.6 to 50.0 mM) or CDDP (from 1.25 to 20.0 mM)
(31). The IC values, defined as the concentrations inhibiting cell
growth relative to control, were determined from the analysis of
dose response-curves obtained after 72 h of exposure. Every
concentration was tested in quadruplicate wells in each experiment
and at least three independent experiments were performed.
The cell lines A549 (a7 AChR +) and NCI-H1975 (a7 AChR -),
weregrowninRPMI1640 supplemented with10%FBS.Cellswere
trypsinized and plated in 24-well plates or 35 mm Petri at densities
of 50 and 100 or 150 and 300 cells/dish for A549 and NCI-H1975,
respectively. Cells were allowed to adhere overnight and then
exposed to either long- chain a-neurotoxin from Naja Kaouthia,a t
concentrationsof15 mM,7.5 mM,3.8 mM(A549)and6 mM,3 mM,
1.5 mM (NCI-H1975), or short-chain a-neurotoxin from Naja Atra,
at concentrations of 30 mM and 15 mM (both cell lines).
Treated cells were then incubated for 7–10 days, until visible
colonies formed. The dishes were then washed in phosphate-
buffered saline, and colonies stained with 1% methylene blue in
methanol for 15 min. Plates were then washed in tap water, and
colonies containing greater than 50 cells were counted on an
inverted microscope. Survival was compared to the plating
efficiency of untreated controls.
Apoptosis was determined by annexin V–FITC and propidium
iodide (PI) double staining (Bender MedSystem,Vienna, Austria),
by fluorescence activated cell-sorting (FACS) (BD Biosciences,
Milan, Italy) analysis [43]. A5409 cells (2.5610
5) were treated for
24 h with 1, 10 and 50 mM a-cobratoxin from N. kaouthia.
Animals
All the procedures involving animals were conducted as
indicated in the Italian National Guidelines (D.L. No. 116 G.U.,
suppl. 40, 18.2.1992, circolare No. 8, G.U. July 1994) and in the
appropriate European Directives (EEC Council Directive 86/609,
1.12.1987), adhering to the Guide for the Care and Use of
Laboratory Animals (United States National Research Council,
1996) and according to an approved protocol reviewed by the
Institutional Animal Care and Use Committee (Genova, 15
November 2004, reference N.149). All the in vivo experiments
reported here were done on the basis of authorization no. 254 of
the Animal Ethics Committee of the IST of Genoa (Italy).
CD1 female mice (Harlan Nossan, Milano, Italy), 6–7 weeks
old, were used for toxicity studies. Mice were allowed a 7-day rest
period before experiments. All mice were housed at 7–9 per cage,
maintained at 22uC with a 12 h light/dark cycle and fed with a
standard diet and water ad libitum.
Non-Obese Diabetic/Severe Combined Immunodeficient
(NOD/SCID) mice (8 week-old) were used for toxin antitumor
activity studies. They were born and housed in specific filter-
capped cages, kept in pathogen-free conditions and maintained in
the facilities within the animal resources centre at the IST of
Genoa in accordance with the recommendations, regulations and
standards approved by the Federation of European Laboratory
Animal Science Association (FELASA).
In vivo toxicity studies and identification of the Maximum
tolerated dose (MTD)
Toxicity of a-neurotoxins was studied in CD1 mice. Animals
were given intravenous injection (i.v.) of single toxin dose (range
0.1–5,0.mg/kg and 0.1–0.5 mg/kg for cobrotoxin and cobratoxin,
respectively) and checked for acute toxicity. Fifteen minutes after
dosing the mice were allowed free access to food and water. The
behavior and number of survivors were checked daily over an
observation period of 14 days. Body weight was recorded every 2
days and was used as an index of toxicity. Animals were sacrificed
by CO2 at the end of the observation period and immediate
autopsy was carried out.
The lethal dose (LD: the dose of a drug or treatment that will
cause death) and maximum tolerated dose (MTD: the highest dose
of a drug or treatment that does not cause unacceptable side
effects) were identified.
In Vivo orthotopic grafting of A549-luc human lung
cancer cells and bioluminescence imaging (BLI) detection
NOD/SCID mice were xenografted with 0.5610
6 human A549-
luc cells/20 ml PBS into the right lung [20]. Treatment started 7
days after surgery to allow tumor development and mimic clinical
behavior. Experiments were carried out according to two different
treatment protocols, as described in Results. Animals were
sacrificed when they showed important symptoms of dyspnoea,
fatigue, inability to reach food and water, emaciation and
excessive decrease in weight loss. Each animal underwent autopsy
to confirm the presence, characteristics and extent of tumor
development.
Bioluminescence imaging (BLI) was carried out weekly by the In
Vivo Imaging System (IVIS) technology (Caliper Life Sciences,
Paris, France) which measures luciferase activity. Mice were
injected i.p. with 200 ml Luciferin at 15 mg/ml (Promega
Madison, Wisconsin, USA) 10 min before imaging and anesthe-
tized by isoflurane. Thereafter, animals were put in the light-
protected chamber of the IVIS imaging system, and photons
emitted were measured over 3 min. Regions of interest (ROI) were
drawn over the area of photon emission and quantified using the
‘‘Living Image’’ software.
Supporting Information
Figure S1 a7 NAchR expression in A549 and A549-luc
cells treated with a–neurotoxins. Cell lines were treated with
0.001, 0.003 and 0.009 mM a–cobratoxin and the expression of
the a7 receptor was measured by qPCR utilizing as calibrator the
RNA of untreated A549 or A549-luc and ß2 Microglobulin as
reference gene. A: A549 a–cobratoxin, B: A549-luc a–cobratoxin;
C: A549-luc a–cobrotoxin. N.D.: Not Determined.
(TIF)
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